Comparative Pharmacology
Head-to-head clinical analysis: APTIVUS versus EMZAHH.
Peer-Reviewed Evidence
Head-to-head clinical analysis: APTIVUS versus EMZAHH.
APTIVUS vs EMZAHH
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
Tipranavir is a nonpeptidic HIV-1 protease inhibitor that binds to the active site of HIV-1 protease, thereby preventing the cleavage of viral polyprotein precursors into functional proteins, resulting in the production of immature, noninfectious viral particles.
EMZAHH is a monoclonal antibody that targets and binds to the human epidermal growth factor receptor 2 (HER2), inhibiting downstream signaling pathways involved in cell proliferation and survival.
Oral: 500 mg twice daily with ritonavir 200 mg twice daily. Oral solution: 500 mg (1.25 mL) twice daily with ritonavir 200 mg twice daily. Must be taken with food.
10 mg orally twice daily without regard to meals.
None Documented
None Documented
Terminal elimination half-life is 2.1 hours during multiple dosing with ritonavir (due to CYP3A inhibition), 5.5 hours when given alone.
Terminal elimination half-life 12 hours, requiring twice-daily dosing for steady state
Fecal (79.5% unchanged), renal (4.4% unchanged).
Renal 40% unchanged, fecal 50% as metabolites, biliary 10%
Category C
Category C
Antiretroviral
Antiretroviral, Integrase Inhibitor + NRTIs